Drug Profile

MVX 220

Alternative Names: MVX-220

Latest Information Update: 29 Oct 2025

Price :

$50 ^*

Note:

Adis is an information provider. We do not sell or distribute actual drugs.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

Originator University of Pennsylvania
Developer MavriX Bio
Class Gene therapies
Mechanism of Action Gene transference; UBE3A protein replacements

Orphan Drug Status

Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

No
New Molecular Entity No

Highest Development Phases

Phase I/II Angelman syndrome

Most Recent Events

23 Oct 2025 Phase-I/II clinical trials in Angelman syndrome (In children, In adults, In adolescents) in USA (Intracisternal) (NCT07181837)
22 Sep 2025 MVX 220 receives Fast Track designation for Angelman syndrome [Intracisternal] in USA
18 Sep 2025 MavriX Bio plans a phase I/II ASCEND-AS first in human trial for Angelman syndrome (In Children, In adults) in October 2025 (Intracisternal, Injection) (NCT07181837)

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com